Personal Genome Diagnostics PlasmaSELECT 64

Personal Genome Diagnostics has launched the PlasmaSELECT 64, a targeted panel for pan-cancer tumor profiling that incorporates proprietary technologies and bioinformatics. It is the first liquid biopsy tumor profiling assay to test for microsatellite instability status, a biomarker for tumor mutational load that helps identify cancer patients who might benefit from checkpoint inhibitors and other immuno-oncology cancer therapies. The panel includes 15 unique biomarkers, 11 of which are associated with active clinical trials. The panel is enabled by the company's proprietary DNA extraction and sample preparation methods, which accommodate low-abundance cell-free DNA samples, as well as hybrid-capture processing in combination with high-coverage, next-generation sequencing. The company's proprietary VariantDx computational algorithms enable discrimination of sequencing artifacts and errors from bona-fide mutations.